Molecular perspective on targeted therapy in breast cancer: a review of current status
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Humana Press Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Breast cancer is categorized at the molecular level according to the status of certain hormone and growth factor receptors, and this classification forms the basis of current diagnosis and treatment. The development of resistance to treatment and recurrence of the disease have led researchers to develop new therapies. In recent years, most of the research in the field of oncology has focused on the development of targeted therapies, which are treatment methods developed directly against molecular abnormalities. Promising advances have been made in clinical trials investigating the effect of these new treatment modalities and their combinations with existing therapeutic treatments in the treatment of breast cancer. Monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates, PI3K/Akt/mTOR pathway inhibitors, cyclin-dependent kinase 4/6 inhibitors, anti-angiogenic drugs, PARP inhibitors are among the targeted therapies used in breast cancer treatment. In this review, we aim to present a molecular view of recently approved target agents used in breast cancer.
Açıklama
Anahtar Kelimeler
Breast cancer, Targeted therapy, PI3K, Akt, mTOR pathway inhibitors, CDK4, 6 inhibitors, PARP inhibitors, Pi3k/Akt/Mtor Pathway, Trastuzumab, Management, Ribociclib, Lapatinib, Neratinib, Radiotherapy, Palbociclib, Inhibitors, Blockade
Kaynak
Medical Oncology
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
39
Sayı
10
